Anxiety News and Research

Latest Anxiety News and Research

Pfizer pleads guilty of defrauding Medicare, Medicaid and other government-funded health care programs

Pfizer, Inc. announced today it has agreed to plead guilty to criminal conduct and to pay more than $2 billion in criminal and civil fines, penalties and damages to settle allegations made in multiple whistleblower lawsuits that the pharmaceutical giant defrauded Medicare, Medicaid and other government-funded health care programs in connection with its market practices for four of its drugs. The settlement is the largest qui tam settlement in U.S. history.

3 Sep 2009

Millennium's sNDA to be reviewed by the FDA

The Takeda Oncology Company today announced the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s supplemental new drug application (sNDA) based on long- term overall survival (OS) data from the landmark VISTA1 trial examining the use of VELCADE based therapy in patients with previously untreated multiple myeloma (MM).

3 Sep 2009

Accuracy of the LENA Autism Screen increased

LENA Foundation has increased the accuracy of the LENA Autism Screen (LAS) to 91 percent for children 24 to 48 months. LAS - the first automatic and totally objective autism screen - is now as accurate or more accurate than other autism screens currently available to parents and clinicians.

3 Sep 2009

University of North Carolina awarded the Center of Excellence in Genomic Science

To seek answers, the National Human Genome Research Institute and the National Institute of Mental Health has named the University of North Carolina at Chapel Hill a Center of Excellence in Genomic Science and awarded UNC $8.6 million over five years to fund a new Center for Integrated Systems Genetics, or CISGen.

2 Sep 2009

Six-month period financial results released by Cannasat Therapeutics

Cannasat Therapeutics Inc., a clinical stage pharmaceutical company developing products to treat neurological disorders such as neuropathic pain and schizophrenia, today announced its results for the six months ended June 30, 2009. Unless specified otherwise, all amounts are in Canadian dollars.

1 Sep 2009

Nighttime acid reflux symptoms impair sleep quality

There has been much debate about the relationship between gastroesophageal reflux disease (GERD) and sleep. Three new studies in Clinical Gastroenterology and Hepatology explore GERD's effect on sleep quality and the health-care system as well as how a widely prescribed sleeping pill may mask the disease.

1 Sep 2009

Study establishes link between workplace bullying and increased sleep disturbances

A study in the Sept.1 issue of the journal SLEEP shows that current or past exposure to workplace bullying is associated with increased sleep disturbances. Associations also were found between observed bullying and sleep disruption, indicating that bullying has detrimental effects even when it is experienced indirectly.

1 Sep 2009

Psychological therapy for breast cancer patients reduces blood inflammation levels

A psychological intervention for newly diagnosed breast cancer patients with symptoms of depression not only relieves patients' depression but also lowers indicators of inflammation in the blood.

1 Sep 2009

Chemotherapy affects sleep-wake activity rhythms of breast cancer patients

A study in the Sept.1 issue of the journal Sleep shows that the sleep-wake activity rhythms of breast cancer patients are impaired during the administration of chemotherapy. Results indicate that the first cycle of chemotherapy is associated with a temporary disruption of these rhythms, while repeated administration of chemotherapy results in progressively worse and more enduring impairments.

1 Sep 2009

Hospital executives worry about reform uncertainties

Hospital executives worry about uncertainties in reform. The Washington Post reports: "Anxiety is running high among hospital executives as they ponder the ever-changing proposals on Capitol Hill. Wary of changes to payment formulas and fiercely protective of their franchise, industry groups are spending millions to lobby Congress.

1 Sep 2009

Cannabis Science enters into an agreement with Leading Points to represent its products to various government and military agencies

Cannabis Science Inc. (OTCBB: CBIS), an emerging pharmaceutical cannabis company is pleased to announce that the company has signed an agreement with Leading Points Corporation to represent its products, services and initiatives to various government and military agencies.

31 Aug 2009

Psychogenics and Astrazeneca sign agreement to identify new compounds for treating Central Nervous System disorders

PsychoGenics Inc. and AstraZeneca have entered into a drug discovery and development agreement to identify compounds that are likely to be useful for the treatment of certain Central Nervous System (CNS) disorders.

31 Aug 2009

ABAM addresses the need for treating patients with addiction issues by introducing a new certification

The American Board of Addiction Medicine (ABAM) has addressed the significant need for treatment of patient's with addiction issues through the establishment of a new certification in the field of addiction medicine. Cesar L. Benarroche, MD is among the first physicians in the United States certified by the American Board of Addiction Medicine, a new independent medical specialty board.

29 Aug 2009

New study reveals that alcohol "abstainers" are at the highest risk of depression

Abstaining from alcohol consumption is associated with an increased risk of depression according to a new study published in Addiction journal.

29 Aug 2009

The Waismann Method of Accelerated Benzodiazepine Neuro-Regulation proves a suitable alternative to traditional benzodiazepine detoxification

The Waismann Method of Accelerated Benzodiazepine Neuro-Regulation (ABNR) involves a safe, medically-assisted withdrawal from Benzodiazepines in a hospital setting. This advanced approach to Benzodiazepine withdrawal offers patients another alternative to traditional benzodiazepine detoxification, which even when done gradually, can be extremely dangerous and even life threatening.

29 Aug 2009

Milestone reached in Biotie Wyeth collaboration for the development of PDE10 inhibitors for schizophrenia

Biotie announced today that it has reached a milestone in its collaboration with Wyeth for the development of PDE10 (phosphodiesterase 10) inhibitors for schizophrenia, triggering a USD 1.0 million milestone payment to Biotie.

28 Aug 2009

Forest Laboratories announces phase 3 trial results for roflumilast

Forest Laboratories, Inc., an international pharmaceutical manufacturer and marketer and Nycomed, a privately owned pharmaceutical company, today announced that results of four phase III trials have been published in the prestigious peer-reviewed medical journal The Lancet showing that roflumilast, a phosphodiesterase 4 (PDE4) inhibitor, improved lung function and reduced exacerbations in patients with moderate to severe COPD.

28 Aug 2009

NIH panel releases report on the pertinence of family health history information in improving health

Though most Americans are familiar with completing a questionnaire about their family health history when visiting health care providers, an independent panel was convened by the National Institutes of Health this week to critically assess exactly what we know and what we need to learn about how this process relates to improving health.

28 Aug 2009

Study reveals that heavy drinkers and teetotalers have higher levels of depression than moderate drinkers

When it comes to alcohol consumption and depression, a new study by a team of Norwegian and British researchers shows that heavy drinkers - but also teetotalers -- have higher levels of depression and anxiety than those who drink moderately.

28 Aug 2009

GI Dynamics to present additional results of mechanisms of actions clinical study

GI Dynamics, a leader in non-surgical treatments for type 2 diabetes and obesity, today announced that additional results from a previously reported clinical study regarding mechanisms of action will be presented on Saturday, August 29, 2009 by Manoel Galvao Neto, M.D., scientific coordinator, Gastro Obeso Center, Sao Paulo, Brazil and lead investigator for the study, at the International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) 14th World Congress in Paris, France.

27 Aug 2009

Anxiety News and Research

Latest Anxiety News and Research

Pfizer pleads guilty of defrauding Medicare, Medicaid and other government-funded health care programs

Millennium's sNDA to be reviewed by the FDA

Accuracy of the LENA Autism Screen increased

University of North Carolina awarded the Center of Excellence in Genomic Science

Six-month period financial results released by Cannasat Therapeutics

Nighttime acid reflux symptoms impair sleep quality

Study establishes link between workplace bullying and increased sleep disturbances

Psychological therapy for breast cancer patients reduces blood inflammation levels

Chemotherapy affects sleep-wake activity rhythms of breast cancer patients

Hospital executives worry about reform uncertainties

Cannabis Science enters into an agreement with Leading Points to represent its products to various government and military agencies

Psychogenics and Astrazeneca sign agreement to identify new compounds for treating Central Nervous System disorders

ABAM addresses the need for treating patients with addiction issues by introducing a new certification

New study reveals that alcohol "abstainers" are at the highest risk of depression

The Waismann Method of Accelerated Benzodiazepine Neuro-Regulation proves a suitable alternative to traditional benzodiazepine detoxification

Milestone reached in Biotie Wyeth collaboration for the development of PDE10 inhibitors for schizophrenia

Forest Laboratories announces phase 3 trial results for roflumilast

NIH panel releases report on the pertinence of family health history information in improving health

Study reveals that heavy drinkers and teetotalers have higher levels of depression than moderate drinkers

GI Dynamics to present additional results of mechanisms of actions clinical study

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Anxiety News and Research

Latest Anxiety News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in